Anaconda biomed, owned by Ysios, announces first-in-human study of Next-generation thrombectomy system
06/11/2019 Nota de prensa ANACONDA BIOMED, OWNED BY YSIOS, ANNOUNCES FIRST-IN-HUMAN STUDY OF NEXT-GENERATION THROMBECTOMY SYSTEM. Trial Data to Support Regulatory Submission to U.S. Food and Drug Administration • Ysios Capital led the 15M€ Series A round in 2017 in an international investors syndicate with Innogest and Omega Funds Anaconda Biomed, a medical technology…